Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering and diagnosed for: metastatic cancer of several entities~* Clinical indicated therapy with PD-1/PD-L1 inhibitors or CTLA-4 antagonists~* Optionally radiotherapy if clinically indicated~* Age at least 18 years~Exclusion Criteria:~* fertile patients who refuse effective contraception during study treatment~* persistent drug and/or alcohol abuse~* patients not able or willing to behave according to study protocol~* patients in care~* patients that are not able to speak German~* patients which are imprisoned according to legal or governmental order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti CTLA-4 (Type: None): The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
- anti PD-1/PD-L1 (Type: None): The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.

Based on this trial design, predict the completion outcome and termination type (if applicable).